Sotagliflozin, a new drug for heart failure, has been approved by the FDA.

Published Date: 27 May 2023

A novel SGLT 1 and 2 inhibitor called sotagliflozin has been approved for use in the US market with the goal of reducing the risk of cardiovascular (CV) events, particularly hospitalizations for heart failure and acute exacerbations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot